



## King's Research Portal

DOI:

[10.1016/S0140-6736\(18\)31178-4](https://doi.org/10.1016/S0140-6736(18)31178-4)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Barakat, M. F., & Simitsis, P. (2018). Percutaneous coronary intervention for stable angina in ORBITA. *Lancet*, 392(10141), 26. [https://doi.org/10.1016/S0140-6736\(18\)31178-4](https://doi.org/10.1016/S0140-6736(18)31178-4)

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### Take down policy

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

# Statistical and Clinical Significance in ORBITA Placebo-Controlled PCI Trial

Mohamad Fahed Barakat,<sup>1,2</sup> Panagiotis Simitsis<sup>2</sup>

<sup>1</sup>Kings College London BHF Centre of Research Excellence, Cardiovascular Division, London, UK.

<sup>2</sup> Kings College Hospital, London, UK.

We applaud ORBITA as a well-executed first placebo-controlled trial of the incremental impact of PCI on exercise time (ET) in stable angina.<sup>1</sup> However, given the study's importance, we were surprised by the statistics. Using an unpaired t-test, the authors compared change in ET between treatment groups and found "no difference" (16.6 seconds, 95%CI: -8.9 to 42.0, p=0.20). However, in parallel randomized trials, mixed effects models such as an analysis of covariance (ANCOVA) are indicated as they carry more precision, correct for baseline imbalances that predispose to regression to the mean, and confer greater statistical power to detect small but clinically meaningful differences.<sup>2,3</sup> According to their exercise protocol,<sup>4</sup> a 16.6 second ET increment (on top of optimal drugs) brought PCI patients up into the  $\geq 7.9$  metabolic equivalent category linked to a 29% relative reduction in mortality.<sup>5</sup> Thus, the treatment effect might be clinically and statistically significant. At baseline, ET was unbalanced and higher in PCI patients ( $528.0 \pm 178.7$  vs  $490.0 \pm 195.0$ ), implying that the treatment effect could be underestimated due to regression to the mean.<sup>2,3</sup> More importantly, an unpaired t-test shows that the end of study ET is statistically higher with PCI ( $556.3 \pm 178.7$  vs  $501.8 \pm 190.9$ , p=0.04) albeit without adjustment. Given that the baseline ET imbalance biases the results against PCI with change-over-time statistics, could the authors give us the ANCOVA p-value after adjustment for baseline ET. Because hesitant use of PCI could conceivably harm patients, it is imperative that the ORBITA results remain publically valid even after more appropriate ANCOVA testing.

1. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. *Lancet* 2017. Published online on November 2. [http://dx.doi.org/10.1016/S0140-6736\(17\)32714-9](http://dx.doi.org/10.1016/S0140-6736(17)32714-9)
2. Vickers AJ, Altman DG. Analysing controlled trials with baseline and follow up measurements. *BMJ* 2001;323:1123-4.
3. Pocock SJ, Bakris G, Bhatt DL, et al. Regression to the mean in SYMPPLICITY HTN-3: implications for design and reporting of future trials. *J Am Coll Cardiol* 2016;68:884-93.
4. Scott AC, Francis DP, Davies LC, et al. Validation of a treadmill exercise test protocol with improved metabolic plateau formation in patients with chronic congestive heart failure. *Am J Cardiol* 2001;87:1328-31.
5. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA* 2009;301:2024-35.